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Abstract

Parkinson’s disease is the second most common neurodegenerative disorder; it affects 1% of the population
over the age of 65. The number of people with Parkinson’s disease is set to rapidly increase due to changing
demographics and there is an unmet clinical need for disease-modifying therapies. The pathological hallmarks of Parkinson’s disease are the progressive degeneration of dopaminergic neurons in the substantia
nigra and their axons which project to the striatum, and the aggregation of α-synuclein; these result in a
range of debilitating motor and non-motor symptoms. The application of neurotrophic factors to protect
and potentially regenerate the remaining dopaminergic neurons is a major area of research interest. However, this strategy has had limited success to date. Clinical trials of two well-known neurotrophic factors, glial
cell line-derived neurotrophic factor and neurturin, have reported limited efficacy in Parkinson’s disease
patients, despite these factors showing potent neurotrophic actions in animal studies. There is therefore a
need to identify other neurotrophic factors that can protect against α-synuclein-induced degeneration of
dopaminergic neurons. The bone morphogenetic protein (BMP) family is the largest subgroup of the transforming growth factor-β superfamily of proteins. BMPs are naturally secreted proteins that play crucial
roles throughout the developing nervous system. Importantly, many BMPs have been shown to be potent
neurotrophic factors for dopaminergic neurons. Here we discuss recent work showing that transcripts for
the BMP receptors and BMP2 are co-expressed with several key markers of dopaminergic neurons in the
human substantia nigra, and evidence for downregulation of BMP2 expression at distinct stages of Parkinson’s disease. We also discuss studies that explored the effects of BMP2 treatment, in in vitro and in vivo
models of Parkinson’s disease. These studies found potent effects of BMP2 on dopaminergic neurites, which
is important given that axon degeneration is increasingly recognized as a key early event in Parkinson’s
disease. Thus, the aim of this mini-review is to give an overview of the BMP family and the BMP-Smad signalling pathway, in addition to reviewing the available evidence demonstrating the potential of BMP2 for
Parkinson’s disease therapy.
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Introduction

Parkinson’s disease (PD) is a common neurodegenerative
disorder, the pathological hallmarks of which are the progressive degeneration of nigrostriatal midbrain dopaminergic (mDA) neurons and intraneuronal inclusions of α-synuclein, known as Lewy bodies and Lewy neurites (Spillantini
et al., 1997; O’Keeffe and Sullivan, 2018). There is increasing
evidence that axonal degeneration, potentially mediated by
α-synuclein, may be a key early event in the pathogenesis of
PD (O’Keeffe and Sullivan, 2018). Since there is a lack of disease-modifying therapies for PD, two experimental therapies
focusing on neuroprotection and neurorepair have been trialed. These are: (i) administration of neurotrophic factors to
protect the remaining mDA neurons from degeneration, and
(ii) grafting of fetal midbrain neurons to replace the mDA
neurons that have been lost (Hegarty et al., 2014a). For the
purpose of this review, we will focus on the former.

Search Strategy and Selection Criteria

For this review we searched NCBI and Science Direct for
1432

literature published from inception to September 28, 2019
for articles referencing one or more of the following: BMP2;
BMP; Neurotrophic Factor; Dopaminergic neurons; Parkinson’s disease.

The Bone Morphogenetic Protein Family

Neurotrophic factors (NTFs) are small secreted proteins that
regulate the development, survival, growth, differentiation
and maturation of discrete neuronal populations (Sullivan
and O’Keeffe, 2016). In PD, two of the most widely studied
dopaminergic NTFs are glial cell line-derived neurotrophic
factor (GDNF) and neurturin, both of which are members
of the transforming growth factor-β (TGF-β) superfamily of
cytokines. GDNF and neurturin showed potent neurotrophic effects in in vitro and in vivo models of PD, which led to
their subsequent clinical testing in PD patients (Nutt et al.,
2003; Patel et al., 2005; Slevin et al., 2005; Lang et al., 2006;
Decressac et al., 2011; Warren Olanow et al., 2015; Whone
et al., 2019a, b). However, these clinical trials have thus far
failed to meet their primary endpoints. Consequently, there

Goulding SR, Sullivan AM, O’Keeffe GW, Collins LM (2020) The potential of bone morphogenetic protein 2 as a neurotrophic factor for
Parkinson’s disease. Neural Regen Res 15(8):1432-1436. doi:10.4103/1673-5374.2743278

is an ongoing need to identify alternative NTFs for dopaminergic neuroprotection in PD. Bone morphogenetic proteins
(BMPs) are being increasingly studied in this regard.
The BMP family is the largest subgroup of the TGF-β
superfamily of proteins and is comprised of at least 20
growth factors, including the growth and differentiation
factor (GDF) family (Kawabata et al., 1998). BMPs were first
identified by their presence in extracts of demineralized
bone (Wozney, 1992) and have since been shown to induce
a sequential developmental cascade of cartilage and bone
formation, as well as playing roles in various other developmental processes (Chen et al., 2004). Experimental evidence
has demonstrated that BMPs are involved in many biological
processes across various cell types, including monocytes, epithelial cells, mesenchymal cells, and importantly, neuronal
cells (Miyazono and Shimanuki, 2008; Wang et al., 2014).
Within these cells, BMPs are known to regulate growth, differentiation, chemotaxis and apoptosis, while also playing
vital roles in the morphogenesis of almost all organs and tissues throughout embryogenesis (Hogan, 1996; Wang et al.,
2014). Additionally, BMPs are crucial regulators of axonal
growth in many distinct neuronal populations (Gratacos et
al., 2002; Parikh et al., 2011; Hegarty et al., 2013a).

Bone Morphogenetic Protein-Smad Signaling

BMPs signal through a canonical pathway that involves transcription factors known as Smads. In this pathway, BMPs
bind to a heterotetrameric complex of cell surface transmembrane type I and type II serine/threonine kinase receptors,
causing the subsequent activation of Smad signaling (Weiss
and Attisano, 2013) (Figure 1). Depending on the cellular
context, BMP signaling can also occur via non-canonical
pathways involving the activation of many intracellular pathways, including GTPases, mitogen activated protein kinase,
and phosphoinositide 3-kinase pathways (Zhang, 2009). To
date, there are seven identified type I receptors, the activin
receptor-like kinases (ALK) 1–7, and five type II receptors
(Hegarty et al., 2013a). There are eight distinct Smad proteins, which constitute three separate functional groupings.
These include the receptor-regulated Smads (R-Smads)-1,
-2, -3, -5, and -8/9, the common-mediator Smad (Co-Smad)
4 and the inhibitory Smads (I-Smads) 6 and 7 (Wrana and
Attisano, 2000). Following ligand binding to the heterotetrameric receptor complex, which is composed of a type I
and type II receptor dimer, the constitutively active type II
receptors intracellularly transphosphorylate the type I receptors at serine and threonine residues via a highly conserved
glycine/serine domain (Wrana and Attisano, 2000). The
phosphorylation of type I receptors leads to the recruitment
and subsequent phosphorylation of the R-Smads, which can
then form a heterotrimer complex with Co-Smad 4. The ISmads function as major negative regulators of BMP-Smad
signaling and compete with the R-Smads for both receptor
binding and Co-Smad 4 binding. The I-Smads also target
the receptors for degradation via the proteasome (Shi and
Massague, 2003). The signaling pathway culminates with the
R-Smads and Co-Smad 4 complex translocating to the nucleus, where it binds to DNA and regulates the transcription of
target genes (Wrana and Attisano, 2000). However, although
there are many ligands of the TGF-β superfamily, there are

Figure 1 Schematic of BMP-Smad signalling from cell membrane to
nucleus.
BMP ligands bind to a heterotetrameric complex of type I and type II
serine/threonine kinase cell surface receptors, causing the constitutively
active type II receptor to intracellularly phosphorylate the type I receptor. R-Smads and I-Smads compete for binding at the receptor complex
for phosphorylation and subsequent complex formation with Co-Smad
4. This complex translocates to the nucleus, where it binds to the DNA
and alters transcription. BMP: Bone morphogenetic protein. BMPR:
BMP receptor; Co-Smad 4: common-mediator Smad 4; I-Smads: inhibitory Smads; R-Smads: receptor-regulated Smads.

very few receptors available to accommodate ligand binding.
Thus, the type I and type II receptors are required to bind to
more than one ligand type (Shi and Massague, 2003). There
are two known type I BMP receptors (BMPRs), BMPR1A
(also known as ALK3) and BMPR1B (also known as ALK6);
however, BMPs are also capable of binding to ALK1 and
2. Furthermore, BMPs can bind to three type II receptors:
BMPR2, activin type 2A receptor and activin type 2B receptor (Hegarty et al., 2013a). Recent studies have identified
dynamin-dependent endocytosis to be a crucial regulator of
the BMPRs at the surface of the cell membrane and to play a
central role in the activation, temporal kinetics and magnitude of BMP signal transduction (Hegarty et al., 2017a).
The type I and II BMPRs can form the heterotetrameric
complex required for Smad activation in various ways; consequently, BMP ligands have varying affinities for these combinations. For example, BMP2 binds to BMPR1A and BMPR1B
with a higher affinity than it does to BMPR2. Similarly, GDF5
binds to BMPR2 and BMPR1B with greater affinity than to
BMPR1A. In fact, the affinity of GDF5 for BMPR1B is at least
15-fold higher than it is for BMPR1A, signifying the fundamental importance of BMPR1B for GDF5 signaling (Nickel
et al., 2005). Such varying affinities for multiple receptor
complexes is relevant when studying the effects of potential
NTFs in different cell lines. In addition, various studies on
the structural and functional features of the BMPRs have
highlighted a cytoplasmic loop segment, known as the L45
loop, located adjacent to the glycine/serine domain on type
I receptors, which is involved in R-Smad binding. A corresponding loop, the L3 loop, is present on the R-Smads and is
1433
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involved in determining the specific Smad substrates for the
type I receptor kinases. Smads 1, 5 and 8 are the pivotal effectors that are primarily linked to members of the BMP/GDF
subfamily, while Smad 2 and 3 are typically associated with
TGF-βs, Activins and Nodals (Mueller and Nickel, 2012).

Bone Morphogenetic Protein Expression in
the Nervous System

Several studies have characterized the temporal expression
profiles of the various BMPs and their receptors in the developing nervous system. BMPR1 and BMPR2 are stably expressed in the brain throughout adulthood, in several regions
including the cortex, striatum, hippocampus and substantia
nigra (SN) (Chen et al., 2003; Miyagi et al., 2011). The expression of BMPR1B and BMPR2 receptors in the rat ventral
mesencephalon (VM) is present from embryonic day (E)
14 onwards, after which it is continuous through to at least
post-natal day (P) 90 (for review see Hegarty et al., 2014b).
Similarly, BMPR1B and BMPR2 transcripts are expressed in
the mouse VM from E12 onwards (Hegarty et al., 2017b).
Notably, this BMPR temporal expression profile parallels the
growth of nigrostriatal dopaminergic projections. While multiple BMPs have been examined as potential NTFs for mDA
neurons (for review see Hegarty et al., 2014b), given recent
data showing that BMP2 is expressed in the human SN, and
that it can protect against neurotoxin and α-synuclein-induced degeneration (Goulding et al., 2019), we will focus on
BMP2 for the purposes of this article.

Neurotrophic Effects of Bone Morphogenetic
Protein 2 in Primary Cultures of Rodent
Midbrain

Within the BMP family, BMP2 is one of the most extensively
studied BMPs. An early paper reported that recombinant
human (rh)BMP2 exerted neurotrophic effects on cultured
E13–15 rat VM mDA neurons (Jordan et al., 1997). Specifically, treatment with 10 ng/mL rhBMP2 increased the
survival of tyrosine hydroxylase-positive (TH+) mDA neurons, by 1.5-fold compared to that in controls, after 8 days
in vitro (DIV). The same study demonstrated that BMP2
treatment of mDA cultures resulted in increased numbers
of 5-bromodeoxyuridine-positive and glial fibrillary acidic
protein-positive cells, markers of cell proliferation and astrocytes, respectively. These early findings indicated not only
does BMP2 promote the survival of mDA neurons, but that
it also appears to play a selective role in the proliferation and
differentiation of neural progenitors.
A further study also demonstrated positive effects of BMP2
treatment on mDA neurons in E14 VM cultures. Specifically,
cultures treated with BMP2 displayed a concentration-dependent increase in the number of mDA neurons, reaching a
maximum increase of 237% after treatment with 10 ng/mL,
compared to vehicle-treated controls after 7 DIV (Reiriz et
al., 1999). In addition, BMP2 treatment increased the number of primary neurites and neurite branching in TH+ cells
in a concentration-dependent manner, reaching a maximal
effect with 1 ng/mL rhBMP2 (Reiriz et al., 1999). Similarly,
other studies have shown a significant increase in the neurite
1434

length of TH+ neurons in E14 rat VM primary cultures after
treatment with 50 ng/mL or 200 ng/mL rhBMP2 (Hegarty
et al., 2014b; Goulding et al., 2019). One study investigated
whether BMP2-induced effects were mediated by astroglial
cells and reported that addition of 10 ng/mL BMP2 had no
effect on the number or morphology of astroglial cells in
E14 VM cultures (Reiriz et al, 1999). They further showed
that BMP2-induced increases in TH+ cell numbers were
not altered in the presence of 30 µM α-aminoadipic acid, a
gliotoxin that eliminates glial fibrillary acidic protein-immunoreactive astrocytes (Reiriz et al., 1999). Interestingly however, this study did report that treatment with 100 ng/mL
BMP2 led to significant increases in both the number and
morphology of astrocytes (Reiriz et al., 1999). These findings suggest that, at low doses, BMP2 treatment promotes
both the number and morphological differentiation of mDA
neurons, while at higher doses, it also influences the number
and phenotype of astroglial cells (Reiriz et al., 1999).
Several studies have reported that the neurotrophic effects
of BMP2 and BMP signalling often occur in tandem with,
and are amplified by, other NTFs. For example, BMP2-induced signalling in E19 rat striatal neurons was found to be
facilitated by co-administration with either BDNF or neurotrophin-3 (Gratacos et al., 2001). However, there is limited
data available on the interactions of BMPs with other NTFs
in the context of dopaminergic neurons, and this will be an
important point to consider in future research.

Neurotrophic Effects of Bone Morphogenetic
Protein 2 in Cell Line Models of Human
Dopaminergic Neurons

In addition to the neurotrophic effects of BMP2 reported in
studies on primary VM cultures, similar effects have been
demonstrated in SH-SY5Y cells, a cell line which, despite
some limitations, is a widely-used in vitro model of human
mDA neurons (Xie et al., 2010; Hegarty et al., 2016; Xicoy et
al., 2017; Goulding et al., 2019). Specifically, SH-SY5Y cells
treated with 50 ng/mL or 200 ng/mL rhBMP2 for 3 or 4 DIV
respectively, displayed an increase in total neurite length (Hegarty et al., 2013b; Goulding et al., 2019). This supported the
previous studies which showed that BMP2 treatment induced
neuronal differentiation of mDA neurons (Reiriz et al., 1999;
Hegarty et al., 2014b; Goulding et al., 2019). Treatment with
BMP2 was also found to activate the canonical Smad 1/5/8
signaling pathway in SH-SY5Y cells to induce neurite growth
(Hegarty et al., 2013b). A causal link between neurite growth
and BMP signaling was demonstrated when it was shown that
pretreatment with dorsomorphin, a selective small molecule
inhibitor of BMPR1 receptors (Yu et al., 2008; Hegarty et al.,
2013b), completely prevented BMP2-induced differentiation
of SHSY5Y cells (Hegarty et al., 2013b). In addition, dorsomorphin treatment completely blocked BMP2-induced Smad
activation. Similar experiments on E14 VM cultures showed
that dorsomorphin blocked both morphological differentiation of mDA neurons and activation of the Smad pathway,
which had been induced by BMP2 treatment (Hegarty et al.,
2013b, 2014b). Collectively, these studies show that the phenotypic effects exerted by BMP2 are directly dependent on
the activation of the Smad 1/5/8 signaling pathway in mDA
neurons (Hegarty et al., 2013b, 2014b).
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Expression of Bone Morphogenetic Protein 2
and Its Receptors in the Human Substantia
Nigra

We have recently shown, using unbiased co-expression
analysis, that the expression of BMP2 and of its receptors is
positively correlated with the expression of five key dopaminergic markers in the human SN, that is ALDH1A1, Nurr1,
Girk2, TH and LMX1B (Goulding et al., 2019). Furthermore,
we have shown that BMP2 is expressed at significantly higher levels in the SN than in the putamen or the cerebellum,
areas that are known to be especially responsive to BMPs.
Interestingly, we have also analyzed open source gene expression data from SN of age- and gender-matched samples
at various Braak stages of PD and found that transcripts
for BMP2 were significantly downregulated at later stages
(Goulding et al., 2019). These data suggest a functional role
for both BMP2 and the BMPRs in dopaminergic neurons
within the human SN.

Protective Effects of Bone Morphogenetic
Protein 2 against Neurotoxin- and
α-Synuclein-Induced Neurodegeneration In
Vitro

On investigating the effects of rhBMP2 in cellular in vitro
models of PD, we found that treatment with 50 ng/mL rhBMP2 for 72 hours increased neurite length by 1.5-fold in SHSY5Y cells and 1.3-fold in E14 VM cultures, compared to
controls (Figure 2). Additionally, BMP2 treatment protected
the survival of TH+ neurons in these mDA neuronal cultures
against reductions induced by either 1-methyl-4-phenylpyridinium iodide or 6-hydroxydopamine (6-OHDA).
Furthermore, treatment with 50 ng/mL rhBMP2 resulted in
significant increases in both neurite length and somal area,
in cultures treated with either 1-methyl-4-phenylpyridinium iodide or 6-OHDA for 72 hours (Goulding et al., 2019).
Additionally, treatment with 50 ng/mL rhBMP2 protected
against wild-type-α-synuclein- and mutant A53T-α-synuclein-induced neurite degeneration in both SH-SY5Y cells and
in mDA neurons after 3 DIV (Goulding et al., 2019). This is
important given that neurite degeneration is an early pathological feature of PD pathogenesis, which may be as a result
of α-synuclein accumulation (O’Keeffe and Sullivan, 2018).

Neurotrophic effects of Bone Morphogenetic
Protein 2 In Vivo

To support the positive neuroprotective effects of BMP2 seen
in the in vitro studies, there are some promising data regarding its in vivo effects. One study reported that pretreatment
with 50 ng/mL rhBMP2 could maintain cell viability in cultures of E14 VM for up to 6 hours, compared to untreated
control cultures which demonstrated a 25% decrease in cell
viability over the same period (Espejo et al., 1999). A subsequent in vivo study showed that treatment of E14 rat VM
with 50 ng/mL rhBMP2 prior to grafting into the striatum
of 6-OHDA-lesioned rats resulted in a significant increase
in the survival of the grafted dopaminergic neurons (Espejo
et al., 1999). This neuroprotective effect of BMP2 pretreat-

ment in vivo was substantial at 1 week after grafting, and remained, although at a lower level, after 4 weeks (Espejo et al.,
1999). After 1 week, the rats that had received BMP2-treated
VM grafts showed no difference in motor impairment, as
measured by apomorphine-induced rotations, than those
that had received untreated VM grafts; however after four
weeks, rats with BMP2-treated VM grafts displayed significant reductions in rotations, compared to those with untreated grafts. Furthermore, the morphology of the grafted
dopaminergic neurons was notably more differentiated in
the rhBMP2 pre-treated group than in the untreated graft
group at 4 weeks post-grafting (Espejo et al., 1999). In light
of these studies showing the in vivo potential of BMP2 treatment, it will be important to test both recombinant BMP2
and viral vectors carrying the BMP2 transgene in neurotoxin
and α-synuclein in vivo models of PD.
As well as the neurotrophic effects of BMP2 described
above, another study has highlighted the potential of BMP2
to induce differentiation of neural stem cells (NSCs) in vitro
(Yan et al., 2016). This is an important finding, given the
low survival rate, and considering the ethical and logistical
difficulties involved, of human fetal VM tissue grafts for PD
treatment (Olanow et al., 2003; Ishii and Eto, 2014). Specifically, Yan et al. (2016) employed five doses of BMP2 (that is
0.1, 1, 10, 20 and 100 ng/mL) over a 14-day period, to treat
NSCs harvested from E14 VM cells. This study found that 20
and 100 ng/mL doses of BMP2 induced the highest increases
in the number of dopaminergic neurons, while also increasing their neurite length (Yan et al., 2016). This effect of BMP2
on NSC differentiation was induced via miR-145-mediated
upregulation of Nurr1, a key player in the maintenance of DA
neurons (Yan et al., 2016). NSCs offer a viable therapeutic
approach to PD therapy as the cells are self-renewing and can
be differentiated into all neural lineage cells, therefore showing promising potential to be used for replacement of those
mDA neurons that are lost from the PD brain.

Conclusion

Here we have reviewed the available evidence that supports
BMP2 as a factor with potential to be used in neurotrophic
therapy for PD. It will be important to determine whether
this BMP ligand is effective in protecting dopaminergic
neurons against α-synuclein-induced degeneration in vivo,
in translational models of PD, such as the α-synuclein rat
model, as the next stage in rationalizing its further study as a
potential therapeutic agent for PD.
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Figure 2 rhBMP2 promotes neurite length in SH-SY5Y cells and in
primary cultures of dopaminergic neurons.
(A) SH-SY5Y cells and (B) TH+ dopaminergic neurons in primary
cultures of E14 rat VM, after treatment with 50 ng/mL rhBMP2 for
72 hours compared to untreated controls. Scale bar: 50 µm. rhBMP2:
Recombinant human bone morphogenetic protein 2; TH+: tyrosine hydroxylase-positive; VM: ventral mesencephalon.
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